| __timestamp | Sarepta Therapeutics, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 49315000 | 10811000 |
| Thursday, January 1, 2015 | 75043000 | 33001000 |
| Friday, January 1, 2016 | 83749000 | 64936000 |
| Sunday, January 1, 2017 | 122682000 | 99909000 |
| Monday, January 1, 2018 | 207761000 | 127724000 |
| Tuesday, January 1, 2019 | 284812000 | 161524000 |
| Wednesday, January 1, 2020 | 317875000 | 182933000 |
| Friday, January 1, 2021 | 282660000 | 219982000 |
| Saturday, January 1, 2022 | 451421000 | 278139000 |
| Sunday, January 1, 2023 | 481871000 | 309799000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Sarepta Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. from 2014 to 2023. Over this period, Sarepta's SG&A expenses surged by nearly 900%, peaking at approximately $482 million in 2023. In contrast, Ultragenyx saw a more modest increase of around 280%, reaching about $310 million in the same year. This stark difference highlights Sarepta's aggressive expansion strategy, while Ultragenyx maintains a more conservative approach. The data reveals a consistent upward trend for both companies, reflecting the growing operational costs in the biotech sector. As these companies continue to innovate, their ability to manage these expenses will be pivotal in sustaining growth and delivering shareholder value.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Ultragenyx Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Zoetis Inc. or Sarepta Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Sarepta Therapeutics, Inc. vs Walgreens Boots Alliance, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Sarepta Therapeutics, Inc. or Evotec SE
Alkermes plc or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.